scholarly journals Pola Penggunaan Insulin Pada Pasien Diabetes Melitus Tipe 2 Rawat Inap Di Rumah Sakit X Pekanbaru Tahun 2014

2017 ◽  
Vol 10 (1) ◽  
pp. 38 ◽  
Author(s):  
Inayah Inayah ◽  
M. Yulis Hamidy ◽  
Roza Putri Rachma Yuki
Keyword(s):  
Type 2 Diabetes ◽  
Medical Records ◽  
Premixed Insulin ◽  
Short Acting ◽  
Acting Insulin ◽  
Short Acting Insulin ◽  
Long Acting ◽  
Insulin Use ◽  
Diabetes Melitus

Insulin is one of pharmacological treatment of type 2 diabetes mellitus (DM). The aim of this study was to know thepattern of insulin use in hospitalized patients with type 2 diabetes Hospital X Pekanbaru. The type of research wasdescriptive. Data retrieved from 63 the medical records of patients with type 2 diabetes at Hospital X Pekanbaruperiod January - December 2014. The most characteristics of subject was average of age 55.40 (± 10.91) years, theaverage of RBG level 313.37 (± 135.81) mg / dL, female (55.6%), financing with BPJS (49.2%), housewives (49.2%),the diagnosis of type 2 diabetes with complications (38.1 %). The most insulin usage according to duration of actionwas short-acting insulin (46.4%), the number of daily doses was <20 IU from all type of insulin. The most combinationof different insulin types (7.9%) was long-acting insulin with rapid-acting insulin and the most combination of insulinand OHD (6.3%) was a short-acting insulin with gluconeogenesis inhibitor and premixed insulin with gluconeogenesisinhibitor.

scholarly journals Comparison of Human Premixed and Basal Plus Short-Acting Insulin Regimens for Individuals With Type 2 Diabetes During Ramadan Fasting

Cureus ◽  
2020 ◽  
Author(s):  
Mahmood Thamer Altemimi ◽  
Samih A Odhaib ◽  
Husam J Imran ◽  
Ali Alhamza ◽  
Ammar M Almomin ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Ramadan Fasting ◽  
Short Acting ◽  
Acting Insulin ◽  
Short Acting Insulin

scholarly journals Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen

2019 ◽  
Vol 7 (1) ◽  
pp. e000679 ◽  
Author(s):  
Jochen Seufert ◽  
Anja Borck ◽  
Peter Bramlage
Keyword(s):  
Basal Insulin ◽  
Fixed Ratio ◽  
Severe Hypoglycemia ◽  
Insulin Regimen ◽  
Premixed Insulin ◽  
Minimal Impact ◽  
Short Acting ◽  
Acting Insulin ◽  
Short Acting Insulin ◽  
Basal Bolus

We summarize here clinical and trial data on a once-daily administration of a single bolus to the meal with the largest expected postprandial glucose excursion (basal-plus), and comment on its clinical utility in the treatment of type 2 diabetes. A PubMed search of data published until September 2018 was taken into consideration and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed. Eighteen reports representing 15 studies were identified (age: 18–80 years; 50–890 patients; follow-up: 8 days to 60 weeks). Data suggest basal-plus is efficacious for improving glycemic control, with a low incidence of (severe) hypoglycemia and minor increases in bodyweight. The timing of short-acting insulin administration and use of different monitoring/titration approaches appear to have minimal impact. When compared with premixed insulin, basal-plus results in largely comparable outcomes. Compared with basal-bolus, it may result in non-inferior glycemic improvements with less weight gain, less hypoglycemia and fewer daily injections. A basal insulin/glucagon-like peptide-1 receptor agonist fixed ratio combination may offer several advantages over the basal-plus regimen, at the cost of gastrointestinal side effects. We conclude that the stepwise introduction of short-acting insulin via the basal-plus strategy represents a viable alternative to a full basal-bolus regimen and may help to overcome barriers associated with multiple injections and anticipated complexity of the insulin regimen.

Sign in / Sign up

Export Citation Format

Share Document